Open day at the ISAE-SUPAERO campus
9.10.2018 11:00:00 EEST | Business Wire | Press release
As part of the Science Fair, organized this year around the theme of 'popular opinion', the ISAE-SUPAERO will open its entire campus to the public on Saturday, October 13 from 10.00 to 18.00. The event is aimed at families, businesses, partners, journalists or alumni (former students) and more than 3,000 people are expected to attend.
Several discussions will take place throughout the day to explain and debunk popular opinion with the general public: "Mechanics is not for girls", "We use only 10% of our brain", "Robots are smart", "Digital simulation is only for geeks", "Astronauts float because there's no gravity", "Laser beams are only used for fighting in science fiction movies", "Aircraft engines pollute the atmosphere and they're noisy", and many more.
Programme at the ISAE-SUPAERO:
➢ Lab visits and scientific demonstrations
➢ Tour of the aero-acoustic wind tunnel - the only facility of its kind in Europe
➢ Demonstrations
➢ Meetings with student clubs
➢ Activities for children
➢ Conference on "How does this aircraft fly safely?"
➢ "My student life at ISAE-SUPAERO" tour with an overview of the engineering curriculum, presentation of digital learning and guided tours of the student campus, sports facilities, residences and the university restaurant
➢ Boutique for kids: a chance to buy ISAE-SUPAERO souvenirs
➢ Show by the student band, Los Soupaéros
Practical information
Free entry - Address: 10 avenue Edouard Belin, 31055 Toulouse. Ring road (Rocade) exit 20. No parking in the vicinity; please use public transport (bus no. 27 and 37, get off at 'Laas CNRS' or 'Supaero'; Metro station 'Faculté de Pharmacie'). ID required for admission. Entrance on avenue Colonel Roche or avenue Edouard Belin. VélôToulouse stations nearby. Drinks and on-site catering available.
About the ISAE-SUPAERO
Global leader in higher education for aerospace engineering, ISAE-SUPAERO offers a unique range of training at the highest level: ISAE-SUPAERO engineer, CNAM-ISAE apprenticeship engineer, Master of Science in "Aerospace Engineering" (in English), 5 research-oriented master degrees, 15 specialized master degrees, 6 doctoral programs. The ISAE-SUPAERO learning community consists of more than 100 full-time professors and researchers and 1,700 students and doctoral students; it also relies on 1,800 lecturers from the professional world. More than 30% of its 650 annual graduates are international students. Its alumni network has more than 21,500 alumni on all continents.
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181009005484/en/
Contact information
OXYGEN TOULOUSE
Cécile MATHEY
cecilem@oxygen-rp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Plus Expands Relationship with SS&C to Support Cross-Border Operations in APAC3.8.2026 04:00:00 EEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that First Plus Asset Management (FPAM), a multi-asset investment management firm, has selected SS&C to provide cross-border operations support across Asia. SS&C will service First Plus across the full investment lifecycle, delivering a scalable, integrated solution supporting transfer agency, order management and execution and investment accounting. FPAM will utilize SS&C to service its growing cross-border operating model and support around $200 million in assets under management*. “As First Plus has expanded, managing our operations has become increasingly complex,” said Jeb Li, Co-Founder and CEO at First Plus. “SS&C’s global footprint and integrated offerings enable us to easily optimize our workflows, so we can focus on scaling quickly and securely while continuing to deliver risk-adjusted returns and best-in-class client service.” The engagement highlights the breadth and scalability of SS&C’s global service model.
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 11:01:00 EEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom